Fascioliasis.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Triosephosphate isomerase from Fasciola hepatica: high-resolution crystal structure as a drug target.Acta crystallographica. Section F, Structural biology communications · 2025
   Article
2. Helminth/Protozoan Coinfections in Chronic Fascioliasis Cases in Human Hyperendemic Areas: High Risk of Multiparasitism Linked to Transmission Aspects and Immunological, Environmental and Social Factors.Tropical medicine and infectious disease · 2025
   Article
3. Enolase and 16.5-kDa Tegument-Associated Protein inJournal of extracellular biology · 2025
   Article
4. A multidisciplinary analysis of over 53,000 fascioliasis patients along the 1995-2019 countrywide spread in Vietnam defines a new epidemiological baseline for One Health approaches.One health (Amsterdam, Netherlands) · 2024
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as